Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

CYP17 polymorphism and tamoxifen-induced hepatic steatosis.

CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Abstract Text:

    takenao ohnishiTakenao Ohnishi,yasuhiro ogawaYasuhiro Ogawa,toshiji saibaraToshiji Saibara,akihito nishiokaAkihito Nishioka,shinji kariyaShinji Kariya,mitsutaka fukumotoMitsutaka Fukumoto,saburo onishiSaburo Onishi,shoji yoshidaShoji Yoshida,

    Hepatic steatosis is a frequent complication, which sometimes develops nonalcoholic steatohepatitis (NASH), in breast cancer patients treated with tamoxifen, a potent antagonist of estrogen. Recently we reported the impairment of fatty acid beta-oxidation and the enhancing fatty infiltration to hepatocytes in aromatase deficiency (ArKO) mice as the estrogen deficiency models. This experimental observation let us speculate strong link between estrogen and hepatic steatosis. In this study, we investigated whether a polymorphism in the cytochrome P450c17alpha gene (CYP17), which is associated with circulating estrogen levels, influences the development of tamoxifen-induced hepatic steatosis. This consecutive study included 180 breast cancer patients undergoing tamoxifen treatment. Genomic DNA extracted from the peripheral blood of each patient was analyzed by restriction fragment length polymorphism (defined as the A1 and A2 alleles). The extent of hepatic steatosis was assessed by computed tomography (CT) as the liver/spleen (L/S) ratio. While receiving adjuvant tamoxifen, 57 of 180 patients developed hepatic steatosis (L/S ratio <0.9) without obvious changes in body mass index (BMI). We observed a significant association between the A2/A2 genotype and the development of hepatic steatosis compared with the A1/A1 genotype [odds ratio (OR), 3.60; 95% confidence interval (C.I.)=1.42-9.10]. The A1/A2 genotype was at an intermediately increased risk of hepatic steatosis (OR, 2.24; 95% C.I.=0.99-5.08). The presence of the A2 allele possibly increased the progression of hepatic steatosis with a gene dosage effect (P=0.06). Our results suggest that functional polymorphism in CYP17 may be involved in determining susceptibility of tamoxifen-induced hepatic steatosis.

    CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Publishing Authors By Initials

    t ohnishiT Ohnishi,y ogawaY Ogawa,t saibaraT Saibara,a nishiokaA Nishioka,s kariyaS Kariya,m fukumotoM Fukumoto,s onishiS Onishi,s yoshidaS Yoshida,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Hepatology research : the official journal of the

    VOLUME: 33

    Page Numbers: 178-80

    Journal Abbreviation:

    ISSN: 1386-6346

    DAY: 7

    MONTH: Oct

    YEAR: 2005

    CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9711801

    CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for CYP17 polymorphism and tamoxifen-induced hepatic steatosis.

    AFFILIATION: Department of Tumor Radiology, Kochi Medical School, Kohau, Okoh-cho, Nankoku-shi, Kochi 783-8505, Japan.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Hepatol Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    CYP17 polymorphism and tamoxifen-induced hepatic steatosis Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News